Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

2.6K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
2.6K
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

4.7K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
4.7K
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

262
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
262
Neurochemical Transmission: Sites of Drug Action01:26

Neurochemical Transmission: Sites of Drug Action

2.0K
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
2.0K
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

880
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
880
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

2.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.3K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Use of Family Relationships in Commercial Claims Data to Characterize Clinical Events of Patients with <i>BRCA1/2</i> Cascade Testing.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science·2026
Same author

TASC: a time-aware sequence clustering framework with uncertainty quantification for electronic health record trajectories.

BioData mining·2026
Same author

Longitudinal TCR repertoires in ulcerative colitis patients show features distinguishing disease states.

Inflammatory bowel diseases·2026
Same author

A multi-metric evaluation of readability in psychiatric discharge summaries.

BioData mining·2026
Same author

A Framework to Quantify Disparities in Pharmacogenomic Treatment Concordance and Drug Response Outcomes.

Clinical and translational science·2026
Same author

Identification of molecular and clinical ALS subgroups based on TDP-43 loss of function molecular markers from population-based patient-derived iPS motor neurons.

bioRxiv : the preprint server for biology·2026
Same journal

Mosquito Species and Gender Identification System Based on Artificial Intelligence and Image Processing Methods.

Journal of computational biology : a journal of computational molecular cell biology·2026
Same journal

GMSA: A Graph Matching and Point Cloud Registration-Based Method for Spatial Transcriptomics Data Alignment.

Journal of computational biology : a journal of computational molecular cell biology·2026
Same journal

Investigations on Multiple Protein Scaffold Filling.

Journal of computational biology : a journal of computational molecular cell biology·2026
Same journal

Cell Type Prediction for Single-Cell RNA Sequencing Utilizing Unsupervised Domain Adaptation and Semi-Supervised Learning.

Journal of computational biology : a journal of computational molecular cell biology·2026
Same journal

PPIGAN: Prediction of Protein-Protein Interactions Using Generative Adversarial Networks.

Journal of computational biology : a journal of computational molecular cell biology·2026
Same journal

Deep Structure-Enhanced Cell Clustering Model for Single-Cell RNA Sequencing Data.

Journal of computational biology : a journal of computational molecular cell biology·2026
查看所有相关文章

相关实验视频

Updated: May 14, 2025

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.1K

DrIVeNN:药物相互作用载体神经网络神经网络

Natalie Wang1,2, Casey Overby Taylor2,3

  • 1Department of Computer Science, Johns Hopkins University Whiting School of Engineering, Baltimore, Maryland, USA.

Journal of computational biology : a journal of computational molecular cell biology
|May 12, 2025
PubMed
概括
此摘要是机器生成的。

预测药物相互作用 (DDI) 对患者安全至关重要. 一个新的模型,DrIVeNN,有效地使用药物特征识别潜在的DDI,优于现有方法,并显示出对心血管疾病等特定领域应用的希望.

关键词:
药物不良事件是药物不良事件.药物 药物相互作用神经网络的神经网络的神经网络多种药房多种药房

更多相关视频

Integration of Animal Behavioral Assessment and Convolutional Neural Network to Study Wasabi-Alcohol Taste-Smell Interaction
06:19

Integration of Animal Behavioral Assessment and Convolutional Neural Network to Study Wasabi-Alcohol Taste-Smell Interaction

Published on: August 16, 2024

351
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.3K

相关实验视频

Last Updated: May 14, 2025

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.1K
Integration of Animal Behavioral Assessment and Convolutional Neural Network to Study Wasabi-Alcohol Taste-Smell Interaction
06:19

Integration of Animal Behavioral Assessment and Convolutional Neural Network to Study Wasabi-Alcohol Taste-Smell Interaction

Published on: August 16, 2024

351
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.3K

科学领域:

  • 药理学和生物信息学 药理学和生物信息学
  • 计算机化药物发现技术
  • 人工智能在医学中的应用

背景情况:

  • 多药性,即使用多种药物,增加了药物不良事件 (ADEs) 的风险,特别是药物相互作用 (DDIs).
  • 预测DDI具有挑战性,因为临床试验无法测试所有药物组合.
  • 患有心血管疾病 (CVD) 的老年人特别容易受到与多药相关的ADEs的影响.

研究的目的:

  • 确定用于预测DDI的关键药物特征.
  • 开发和评估用于DDI预测的新型计算模型.
  • 评估模型在CVD特定案例研究中的表现.

主要方法:

  • 开发了一个双层神经网络,DrIVeNN (药物相互作用载体神经网络).
  • 纳入药物特征,包括分子结构,药物蛋白相互作用和单一药物的副作用.
  • 利用公开的副作用数据库进行模型培训和评估.

主要成果:

  • 与最先进的模型 (DGNN-DDI,KGDDI,NNPS) 相比,DrIVeNN实现了更高的性能.
  • 在DrIVeNN中,AUROC的平均值为0.934,AUPRC的平均值为0.920.
  • 一个特定领域的CVD病例研究显示,DDI预测的平均AUROC为0.979,提高了性能.

结论:

  • DrIVeNN 模型显示了预测多药性ADEs的巨大潜力.
  • 域特定模型可以进一步提高DDI预测的准确性.
  • 这项研究推进了药物安全性预测建模技术.